We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Aventis Declines Sanofi Offer of $61 Billion

By Biotechdaily staff writers
Posted on 06 Feb 2004
In a move to create the third largest pharmaceutical company in the world, Sanofi-Synthelabo SA (Paris, France) has made a hostile bid of U.S.$61 billion for Aventis SA (Strasbourg, France), which has been declined. More...
However, industry analysts say this may be only the first phase of a long takeover fight.

According to Sanofi, the combined company would benefit from a large portfolio of high-growth drugs, with nine products that individually generated sales of more than $600 million in 2003 and firmly established positions in high-growth fields such as cardiovascular, thrombosis, diabetes, central nervous system, urology, internal medicine, and vaccines. The offer has already been approved by Sanofi's board.

"After a review and consideration of the terms and conditions of the unsolicited offer put forward by Sanofi-Synthelabo on Monday, January 26, 2004, the Supervisory Board of Aventis has unanimously concluded today that this bid is not in the best interest of Aventis shareholders and employees. Consequently, the Supervisory Board recommends to the shareholders of Aventis to reject this hostile bid,” Jurgen Dormann, chairman, and Jean-Rene Fourtou, vice chairman.




Related Links:
Sanofi-Synthelabo
Aventis

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
HPV Test
Allplex HPV28 Detection
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.